Vinay Varadan, New York US
Vinay Varadan, New York, NY US
Patent application number | Description | Published |
---|---|---|
20120004855 | METHYLATION BIOMARKERS FOR PREDICTING RELAPSE FREE SURVIVAL - A methylation classification list comprising loci DNA, for which loci the methylation status of the DNA is indicative of likelihood of recurrence of cancer, is provided. Furthermore, a method, apparatus and use for predicting probability of relapse free survival of a subject diagnosed with cancer, are provided. | 01-05-2012 |
20120109678 | DEVICE AND METHOD FOR COMPARING MOLECULAR SIGNATURES | 05-03-2012 |
20120172238 | METHOD AND COMPOSITIONS FOR ASSISTING IN DIAGNOSING AND/OR MONITORING BREAST CANCER PROGRESSION - The present invention relates to a method for assisting in diagnosing breast cancer and/or monitoring breast cancer progression in a given sample based on the analysis of differential DNA methylation patterns. More particularly, the method is directed to the identification of one or more epigenetic markers that derive from the application of a variety of statistical methods in order to point out the prognostic significance of the difference in methylation states at one or more genomic loci and predict whether the sample analyzed has a good or bad prognosis following treatment. | 07-05-2012 |
20120265446 | BIOMARKERS BASED ON SETS OF MOLECULAR SIGNATURES | 10-18-2012 |
20130196877 | IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS - The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said bio-medical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10,FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system. | 08-01-2013 |
20130282404 | INTEGRATED ACCESS TO AND INTERATION WITH MULTIPLICITY OF CLINICA DATA ANALYTIC MODULES - A state machine ( | 10-24-2013 |
20140040264 | METHOD FOR ESTIMATION OF INFORMATION FLOW IN BIOLOGICAL NETWORKS - The present invention relates to a method for stratifying a patient into a clinically relevant group comprising the identification of the probability of an alteration within one or more sets of molecular data from a patient sample in comparison to a database of molecular data of known phenotypes, the inference of the activity of a biological network on the basis of the probabilities, the identification of a network information flow probability for the patient via the probability of interactions in the network, the creation of multiple instances of network information flow for the patient sample and the calculation of the distance of the patient from other subjects in a patient database using multiple instances of the network information flow. The invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy wherein the biomedical marker or group of biomedical markers comprises altered biological pathway markers, as well as to an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer. Furthermore, a corresponding clinical decision support system is provided. | 02-06-2014 |
20140365243 | RETROACTIVE EXTRACTION OF CLINICALLY RELEVANT INFORMATION FROM PATIENT SEQUENCING DATA FOR CLINICAL DECISION SUPPORT - A catalog ( | 12-11-2014 |
20140379379 | SYSTEM AND METHOD FOR REAL TIME CLINICAL QUESTIONS PRESENTATION AND MANAGEMENT - In a clinical decision support method, outputs of computer-implemented analytical modules are computed for a patient. Information is displayed for the patient pertaining to a clinical question comprising outputs computed for the patient of analytical modules associated with the clinical question. The analytical modules may include modules configured to perform in silico genetic/genomic tests using genetic/genome sequencing (whole genome, whole exome, whole transcriptome, targeted gene panels, etc) or microarray data. A clinical question-module matrix (CQ-M matrix) may be generated for the patient associating clinical questions with analytical modules, and the method may further include populating the clinical questions with outputs computed for the patient of the analytical modules associated with the clinical questions by the CQ-M matrix. Such populating advantageously re-uses outputs computed for the patient when an analytical module is associated with two or more different clinical questions by the CQ-M matrix. This system empowers the clinician to focus on the clinical aspects of patient management while allowing the data complexities of patient genomic data interpretation to be handled by the clinical decision support system. | 12-25-2014 |
20150058322 | PATHWAY VISUALIZATION FOR CLINICAL DECISION SUPPORT - When generating visual representations of gene activity pathways for clinical decision support, a validated pathway database that stores a plurality of validated pathways is accessed, wherein each pathway describes at least one interaction between a plurality of genes. A processor ( | 02-26-2015 |